BioLife
Financials
2023 Fiscal Year Annual Revenue
$29.83 Billion
2023 Fiscal Year Gross Profit
$20.61 Billion
2023 Fiscal Year Annual Net Income
$2.35 Billion
2023 Fiscal Year Net Income Growth
14.59%
2023 Number of U.S. Stores
233
Credit Rating
Leases are guaranteed by Baxalta, Inc. or Takeda Pharmaceuticals U.S.A., Inc, which are wholly-owned subsidiaries of Takeda Pharmaceutical Co. Ltd., which is S&P Rated: Investment Grade BBB+ (Long-Term) A-2 (Short-Term)
BioLife
BioLife Plasma Services is a subsidiary of Takeda Pharmaceutical Company Limited (NYSE:TAK), specializing in the collection of high-quality plasma. This plasma is essential for the creation of therapies and treatments for various medical conditions. BioLife operates under strict safety and quality guidelines, ensuring the plasma collected is of the highest standard. Their role in the healthcare sector is significant, as they provide a critical component for the production of life-saving biopharmaceutical products. The financials and credit ratings presented are representative of the consolidated results of Takeda Pharmaceutical Company, which is BioLife Plasma Services's parent entity.